Ch. 4 Psychopharmacology (book stuff) 100% Verified Review 2024/2025
HW Question 1: Identify the priority safety concerns for each class of psychotropic
... [Show More] medications:
Anti-anxiety agents - ANS--tolerance and physical dependence
-abrupt withdrawal can be life threatening
-s/s: sweating, agitation, tremors, n/v, delirium, seizures
-drowsiness, confusion, lethargy
-increases the effect of other CNS depressants, antihistamines
-may aggravate s/s of depression
-orthostatic hypotension
-paradoxical excitement (opposite from the desired effect)
-blood dyscrasias (sore throat, fever, bruising, bleeding)
-congenital malformations have been associated with use of these drugs during the first trimester of
pregnancy
HW Question 1: Identify the priority safety concerns for each class of psychotropic medications:
anti-depressants - ANS--increased risk for suicide
-sedation
-discontinuation syndrome:
>>SSRIs=dizziness, lethargy, headache, nausea
>>TCAs=hypomania, akathisia, cardiac arrhythmias GI upset, panic attacks
>>MAOIs=flu-like symptoms confusion, hypomania
-photosensitivity
-orthostatic hypotension (TCA)
-Tachycardia, arrhythmias (TCA)
-Hyponatremia (SSRI), especially among the elderly
-blurred vision (TCAs and heterocyclics)
-constipation
HW Question 1: Identify the priority safety concerns for each class of psychotropic medications:
Mood stabilizers - ANS--lithium toxicity:
>1.2 mEq/L: vomiting, diarrhea
>2.0: tremors, sedation, confusion
>3.5: delirium, seizures, coma, cardiovascular collapse, death
-increased risk of suicide for all antiepileptics
-hyponatremia
-Steven Johnson Syndrome
-hypotension, arrhythmia (lithium)
-blood dyscrasias (Valproic acid, carbamazepine)
-increased risk of birth defects (anticonvulsant/mood stabilizers)
-drowsiness (lithium and all anticonvulsants)
Question 1: Identify the priority safety concerns for each class of psychotropic medications:
anti-psychotics - ANS--EPS
-hyperglycemia, weight gain, diabetes (atypical antipsychotics)
-hypotension
-orthostatic hypotension... [Show Less]